NRSN — Neurosense Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Neurosense CEO Provides Q1 2023 Update Phase 2B Als Trial Achieves 80% Enrollment
Brief: Neurosense Therapeutics & Massachusetts General Hospital's Neuroepigenetics Lab To Collaborate On Elucidating Neurotherapeutic Effects Of Primec In Als
Brief: Neurosense To Present At The Als And Alzheimer's Disease At Ad/Pd™ 2023 Advances In Science & Therapy Conference
Brief: NeuroSense And QuantalX Collaborate To Improve Early Detection And Treatment Of Neurodegenerative Diseases
U.S. STOCKS ON THE MOVE-Alibaba Group, TripAdvisor, MGM Resorts
U.S. STOCKS ON THE MOVE-Alphabet, Fox Corp, New York Times
NeuroSense rises on approval in Germany to enroll patients in mid-stage ALS trial
Brief: Neurosense Expands Its Phase 2B ALS Trial To Canada And Withdraws Protocol From U.S. IND
Brief: Neurosense Therapeutics Ltd Files For Mixed Shelf Of Up To $100 Mln - SEC Filing
U.S. STOCKS ON THE MOVE-Walt Disney, Personalis, Netflix
NeuroSense jumps on data from combination platform therapy for Alzheimer's
Brief: Neurosense Therapeutics Reports Positive Final Results From Alzheimer's Biomarker Study
Brief: Neurosense Announces Third Quarter 2022 Financial Results And Provides Business Update
Brief: Neurosense Announces Third Quarter 2022 Financial Results And Provides Business Update
NeuroSense rises after Italy allows ALS study enrollment
Brief: Neurosense Receives Regulatory Approval To Commence Patient Enrollment In Italy For Phase 2B Trial In ALS
Brief: Neurosense Receives FDA Clearance Of IND For Its ALS Phase 2B Study
NeuroSense Therapeutics up as FDA permits patient enrolment in ALS drug study
Brief: Neurosense Therapeutics Provides CEO's Q3 Update